If cleared by the European Commission, Abecma would be available for third-line use in the EU’s 27 member countries, a needed boost for a medicine that’s losing ground to Johnson & Johnson’s rival therapy Carvykti.
Both medicines are part of a new class of multiple myeloma treatments that work by targeting a protein called BCMA on diseased cells. They’ve proven powerfully effective in later lines of care, and are now moving earlier, as testing proves additional benefits.
